2nd week of tirzepatide Skipping a Tirzepatide: Effects and Safe Resumption What to Expect on Tirzepatide:

When in doubt about medication integrity, the safest approach is to obtain a fresh supply rather than risk using potentially compromised medication

Follow our page for more such updates: News Source: #ObesityTherapeutics #GLP1 #TernsPharma #ObesityTreatment #ClinicalTrials #PharmaInnovation #MetabolicHealth #BiotechNews To view or add a comment, sign in Terns Pharmaceuticals Halts Obesity Program After Underwhelming Phase 2 Data for Oral GLP-1 (TERN-601) Terns Pharmaceuticals announced topline 12-week Phase 2 FALCON results for its once-daily oral GLP-1 receptor agonist TERN-601 in adults with obesity (BMI 2750 kg/m, without diabetes), showing modest placebo-adjusted weight loss of 4.6%, below internal efficacy targets

one glass of electrolytes for every two alcoholic drinks

Researchers are also investigating whether these medications may lower cardiovascular risk by improving blood pressure, lipid levels, visceral fat, and inflammatory markers simultaneously